Literature for RR-11a (C13.004 inhibitor)
(Topics flags: T Target, K Knockout, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)
-
Ren,Y.C., Zhao,Q., He,Y., Li,B., Wu,Z., Dai,J., Wen,L., Wang,X. and Hu,G.
Legumain promotes fibrogenesis in chronic pancreatitis via activation of transforming growth factor beta1
J Mol Med (Berl) (2020) PubMed Europe PubMed DOI T I -
Wang,D., Xiong,M., Chen,C., Du,L., Liu,Z., Shi,Y., Zhang,M., Gong,J., Song,X., Xiang,R., Liu,E. and Tan,X.
Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy
Kidney Int (2018) 94, 91-101. PubMed Europe PubMed DOI K I -
Shen,L., Li,H., Shi,Y., Wang,D., Gong,J., Xun,J., Zhou,S., Xiang,R. and Tan,X.
M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma
Sci Rep (2016) 6, 30347-30347. PubMed Europe PubMed DOI I -
Gomez-Cabrero,A., Wrasidlo,W. and Reisfeld,R.A.
IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model
PLoS ONE (2013) 8, e73607-e73607. PubMed Europe PubMed DOI PMC EPMC I -
Liao,D., Liu,Z., Wrasidlo,W., Chen,T., Luo,Y., Xiang,R. and Reisfeld,R.A.
Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity
Nanomedicine (2011) 7, 665-673. PubMed Europe PubMed DOI I -
[YEAR:8-4-2004]Ekici,O.D., Gotz,M.G., James,K.E., Li,Z.Z., Rukamp,B.J., Asgian,J.L., Caffrey,C.R., Hansell,E., Dvorak,J., McKerrow,J.H., Potempa,J., Travis,J., Mikolajczyk,J., Salvesen,G.S. and Powers,J.C.
Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases
J Med Chem (8-4-2004) 47, 1889-1892. PubMed Europe PubMed DOI I
2020
2018
2016
2013
2011
2004
